BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33420030)

  • 1. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis.
    Wang X; Hu LP; Qin WT; Yang Q; Chen DY; Li Q; Zhou KX; Huang PQ; Xu CJ; Li J; Yao LL; Wang YH; Tian GA; Yang JY; Yang MW; Liu DJ; Sun YW; Jiang SH; Zhang XL; Zhang ZG
    Nat Commun; 2021 Jan; 12(1):174. PubMed ID: 33420030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils.
    Audrito V
    Purinergic Signal; 2021 Jun; 17(2):173-174. PubMed ID: 33786722
    [No Abstract]   [Full Text] [Related]  

  • 3. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.
    Liu X; Zhou Z; Cheng Q; Wang H; Cao H; Xu Q; Tuo Y; Jiang L; Zou Y; Ren H; Xiang M
    Cell Death Dis; 2017 Sep; 8(9):e3033. PubMed ID: 28880262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
    Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
    Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.
    Spear S; Candido JB; McDermott JR; Ghirelli C; Maniati E; Beers SA; Balkwill FR; Kocher HM; Capasso M
    Front Immunol; 2019; 10():542. PubMed ID: 30972056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts.
    Takesue S; Ohuchida K; Shinkawa T; Otsubo Y; Matsumoto S; Sagara A; Yonenaga A; Ando Y; Kibe S; Nakayama H; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Toma H; Tominaga Y; Mizumoto K; Hashizume M; Nakamura M
    Int J Oncol; 2020 Feb; 56(2):596-605. PubMed ID: 31894273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer.
    Kenkel JA; Tseng WW; Davidson MG; Tolentino LL; Choi O; Bhattacharya N; Seeley ES; Winer DA; Reticker-Flynn NE; Engleman EG
    Cancer Res; 2017 Aug; 77(15):4158-4170. PubMed ID: 28611041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways.
    Ho WJ; Erbe R; Danilova L; Phyo Z; Bigelow E; Stein-O'Brien G; Thomas DL; Charmsaz S; Gross N; Woolman S; Cruz K; Munday RM; Zaidi N; Armstrong TD; Sztein MB; Yarchoan M; Thompson ED; Jaffee EM; Fertig EJ
    Genome Biol; 2021 May; 22(1):154. PubMed ID: 33985562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
    Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
    Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.